A Phase 2 interventional study of Iptacopan and Placebo in Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 40 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · France.
Among the 33 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in France, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 2, reaches primary completion later than 1 of the 13 other live ones, and was the 26th registered.
158 studies on the registry are indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; 76 are open to participants now.
Browse Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies →10 of the 33 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18–70
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Fate Therapeutics · Sites in France, United States, Sweden and 1 more country
Ages 12–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 56 Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis studies recruiting now, 21 (38%) set no upper age limit and 28 (50%) stop at 75 or younger; 9 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 84 is above the median of 36 across 117 interventional studies indexed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
Median enrollment 99 across the 20 interventional studies, 146 across the 13 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 2 studies filed under Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis — fewer than ten, so there is no comparison to draw.
4 of the studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06388941Novartis PharmaceuticalsIptacopan in Patients With ANCA Associated Vasculitis | 2026-12-30 |
| NCT07077304Assistance Publique - Hôpitaux de ParisEACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases | 2027-08-31 |
| NCT06308978Fate TherapeuticsA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | 2027-09-30 |
| NCT07160608Alexion Pharmaceuticals, Inc.Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | 2027-10-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 33 studies in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.
This is a randomized, controlled study to evaluate the efficacy and safety of iptacopan in combination with RTX induction therapy for the treatment of newly diagnosed or relapsed patients with active GPA or MPA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LNP023 administered orally
Drug: Iptacopan · Drug: Rituximab
Matching placebo
Drug: Placebo · Drug: Rituximab
Sustained remission through Week 48 defined as complete remission at Week 24 without major relapse up to Week 48.
To assess the effect of iptacopan in achieving sustained remission compared to standard of care (SOC)
Time frame: At Week 48
B cell counts
To assess participant's immune status
Time frame: At Week 48
Total IgG levels
To assess participant's immune status
Time frame: At Week 48
Complete remission at week 24
Remission is defined as Birmingham Vasculitis Activity Score (BVAS) equal zero. BVAS captures various vasculitis organ manifestations as weighted score describing persistent and new symptoms with higher scores indicating more severe disease.
Time frame: At week 24
Time to reach BVAS=0
To assess time to remission through Week 24
Time frame: At Week 24
Time to major relapse
To assess the effect of iptacopan on disease relapse
Time frame: At Week 48
Estimated glomerular filtration rate (eGFR) using the CKD-EPI formula, urinary protein excretion and hematuria over 48 weeks
To assess the effect of iptacopan on renal function
Time frame: At Week 48
Cumulative dose of glucocorticoid (GC)
To assess the effect of iptacopan on GC sparing
Time frame: At Week 48
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Iptacopan
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis →